

Table 1 Summary of the clinical results (Adopted from Yoshimura et al., 2016)

-	Vaccination and Dex n=37	Dexalone n=36
PSA response rates (%)	-	
>50%decline	22 (59.6)	19 (54.3)
>90%decline	5 (13.5)	7 (20.0)
PSA progression-free survival,median,d	665	210
Median 95%CI	277-1054	156-264
Hazard ratio(95%CI)	0.39 (0.22-0.68)	
<i>p</i> value	0.0076	
Time to chemotherapy initiation, median, d	1576	719
Median 95% CI	1203-1949	634-804
Hazard ratio (95% CI)	0.50 (0.25-1.003)	
<i>p</i> value	0.047	
Overall survival, median, d	2219	1054
Median 95%CI	1546-2892	769-1340
Hazard ratio(95% CI)	0.41(0.21-0.83)	
<i>p</i> value	0.00084	
Cancer death	10	25

Table caption: CI=confidence interval; Dex=dexamethasone; PSA=prostate-specific antigen